Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IMD-0354 (IKK2 Inhibitor V) 是一种选择性IKKβ抑制剂,能够抑制 NF-κB 活性。它能够抑制 TNF-α 诱导的 NF-κB 转录活性,IC50=1.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 298 | 现货 | ||
5 mg | ¥ 498 | 现货 | ||
10 mg | ¥ 697 | 现货 | ||
25 mg | ¥ 1,420 | 现货 | ||
50 mg | ¥ 2,510 | 现货 | ||
100 mg | ¥ 3,760 | 现货 | ||
500 mg | ¥ 7,920 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 519 | 现货 |
产品描述 | IMD-0354 (IKK2 Inhibitor V) is an IKKβ inhibitor and inhibits IκBα phosphorylation in NF-κB pathway. |
靶点活性 | NF-κB:1.2 μM (IC50) |
体外活性 | IMD-0354(<5 μM)抑制了HMC-1细胞中NF-κB的表达以及NF-κB向细胞核的转移。IMD-0354以时间和剂量依赖的方式抑制HMC-1细胞的增殖。IMD-0354(0.5 μM)几乎完全抑制了IC-2 g559细胞和IC-2V814细胞的增殖。IMD-0354(0.5 μM)导致HMC-1细胞周期在G0/G1阶段停滞。IMD-0354(1 μM)增加了HMC-1细胞中具有低二倍体DNA含量的细胞数。IMD-0354(<1 μM)降低了HMC-1细胞中处于S和G2/M阶段的细胞比例。IMD-0354(1 μM)降低了HMC-1细胞中Cyclin D3表达以及pRb磷酸化水平,且这一作用随时间依赖增加。在高浓度下,IMD-0354(<10 μM)对HMC-1细胞中STAT3和STAT6的信号无影响,而STAT1和STAT5的磷酸化略有抑制。在剂量依赖的方式下,IMD-0354抑制了CBhCMCs中NF-κB向细胞核的转移,持续24小时。[1]在HepG2细胞中,IMD-0354以10 μg/ml的浓度抑制了98.5%的NF-κB活性。[2]IMD-0354(1 μM)改善了在同时给予TNFα(6 nM)和胰岛素(100 nM)的情况下,TNFα引起的3T3-L1脂肪细胞星化12小时后培养基中的脂联素浓度下降,以及TNFα治疗下调的Akt磷酸化恢复。[3]IMD-0354(1 μM)抑制了由肿瘤坏死因子-α(TNF-α)引起的IκBα磷酸化和NF-κB核内转移,在培养的心肌细胞中显著减少TNF-α诱导的白介素-1β和单核细胞趋化蛋白-1的产生。[4] |
体内活性 | IMD-0354 at 5 mg/kg also significantly decreases NF-κB, but the magnitude of the decrease is lower than with 20 mg/kg IMD-0354 in lungs of OVA-sensitized mice. IMD-0354 (20 mg/kg) ameliorates airway hyperresponsiveness and reduces the numbers of bronchial eosinophils and mucus-producing cells in OVA-sensitized mice. IMD-0354 (20 mg/kg) also reduces the total numbers of cells and eosinophils in bronchoalveolar lavage fluid in OVA-sensitized mice. IMD-0354 (20 mg/kg) inhibits the production of Th2 cytokines such as interleukin (IL)-5 and IL-13 and eotaxin in the airways and/or lungs of OVA-sensitized mice, but it does not affect the restoration of Th1 cytokines such as IL-12 and interferon-gamma under the same experimental conditions. IMD-0354 (20 mg/kg) results in a partial decrease in serum IgE concentration in OVA-sensitized mice. [2] IMD-0354 significantly decreases the plasma glucose levels in KKAy mice treated with and fed an HF diet in an dose-dependent manner without influence of body weight. [3] IMD-0354 (10 mg/kg) results in a significant dose-dependent reduction of the infarction area/area at risk ratio and the preservation of fractional shortening ratio. [4] |
激酶实验 | In vitro mTOR kinase assays : The reaction mixture consisted of the following components in 10 μL assay buffer (50 mM Hepes pH 7.5, 10 mM MgCl 2, 3 mM MnCl 2, 1 mM EGTA, 2 mM DTT, 0.01%Tween-20): 0.10 μg/mL of in-house generated mTOR enzyme, 0.05 μM ULight-eIF4E-binding protein 1 (Thr37/46) peptide and 10 μM ATP. The mixture is incubated for 60 min at room temperature. 10 μL of Detection mixture consisted of 16 mM EDTA, 0.004 mM Eu-W1024-labeled Anti-Phospho-eIF4E-binding protein 1-(Thr37/46) antibody and 1X LANCE? Detection Buffer is then added and incubated for 60 min. |
细胞实验 | Cells (2×105 cells/mL) are incubated in phenol red free α-MEM containing 10% FCS (for HMC-1 and IC-2 cells) or 5% FCS (for CBhCMCs), and antibiotics with or without various concentrations of IMD-0354, STI571, or PDTC. IC-2WT cells and CBhCMCs are incubated in the presence of 100 ng/mL recombinant rat or recombinant human SCF. One hundred microliters of cell suspension is applied to each well of 96-well culture plates and are incubated for 24, 48, and 72 hours. Before 4 hours from the end of the culture, 10 μL of 5 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) dissolves in PBS is added to each well. The reaction is stopped with the addition of 100 μL of 10% SDS in 0.01 N HCl. Absorbance is measured at 577 nm with ImmunoMini NJ-2300.(Only for Reference) |
别名 | IKK2 Inhibitor V, IMD 0354 |
分子量 | 383.67 |
分子式 | C15H8ClF6NO2 |
CAS No. | 978-62-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 38.4 mg/mL (100 mM)
Ethanol: 38.4 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.6064 mL | 13.032 mL | 26.0641 mL | 65.1602 mL |
5 mM | 0.5213 mL | 2.6064 mL | 5.2128 mL | 13.032 mL | |
10 mM | 0.2606 mL | 1.3032 mL | 2.6064 mL | 6.516 mL | |
20 mM | 0.1303 mL | 0.6516 mL | 1.3032 mL | 3.258 mL | |
50 mM | 0.0521 mL | 0.2606 mL | 0.5213 mL | 1.3032 mL | |
100 mM | 0.0261 mL | 0.1303 mL | 0.2606 mL | 0.6516 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
IMD-0354 978-62-1 NF-Κb IκB/IKK IκB kinase Inhibitor I kappa B kinase IKK2 Inhibitor V IKK IMD0354 inhibit IMD 0354 inhibitor